Direct Detection of Bloodstream Pathogens from Whole Blood Using the Workflow from the DNAe BSI/AMR Test: The First NGS Sample-To-Result Solution
INTRODUCTION
Sepsis is a significant life-threatening condition with 48.9 million cases per year leading to 11 million deaths worldwide1. Patient outcomes are directly related to the timely diagnosis and identification of the pathogen and administration of the appropriate antibiotic treatment. However, traditional standard of care methods like blood culture are labor intensive, slow and take days for actionable results, and limited to detection of organisms that can grow in blood culture. DNAe is developing the first rapid, sample-to-result, next-generation sequencing (NGS) solution, the DNAe bloodstream infections/antimicrobial resistance (BSI/AMR Test), for identification of bacterial and fungal targets directly from whole blood within a work shift compared to days for the current standard of care.
